Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Onconova Therapeutic (ONTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 25,512
  • Shares Outstanding, K 9,850
  • Annual Sales, $ 5,550 K
  • Annual Income, $ -19,670 K
  • 36-Month Beta 0.11
  • Price/Sales 4.71
  • Price/Cash Flow 0.00
  • Price/Book 57.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.46 +73.29%
on 09/29/17
2.83 -10.60%
on 10/12/17
+0.80 (+46.24%)
since 09/15/17
3-Month
1.46 +73.29%
on 09/29/17
2.83 -10.60%
on 10/12/17
+0.43 (+20.48%)
since 07/17/17
52-Week
1.46 +73.29%
on 09/29/17
3.88 -34.79%
on 04/04/17
-0.12 (-4.53%)
since 10/17/16

Most Recent Stories

More News
Today's Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento Therapeutics

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / It wasn't any company news that had shares of Onconova and Sorrento Therapeutics flying higher on Monday but instead recent analyst ratings and coverage...

SRNE : 2.85 (-4.36%)
ONTX : 2.51 (-3.09%)
Onconova Therapeutics to Present Updates at Two Investor Conferences in October

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...

ONTX : 2.51 (-3.09%)
Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...

ONTX : 2.51 (-3.09%)
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates

Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), and Onconova Therapeutics (Nasdaq:ONTX) today announced that they have entered into...

CLRB : 1.73 (+1.17%)
ONTX : 2.51 (-3.09%)
Onconova Therapeutics to Participate in Two Investor Conferences in September

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...

ONTX : 2.51 (-3.09%)
Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric "RASopathies"

-- Company to highlight approaches for studying rigosertib in multiple rare diseases associated with RAS gene at upcoming scientific conference

ONTX : 2.51 (-3.09%)
Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

-- Oral Rigosertib combined with Azacitidine administered to patients with treatment naive and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in difficult-to-treat...

ONTX : 2.51 (-3.09%)
Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...

ONTX : 2.51 (-3.09%)
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes,...

ONTX : 2.51 (-3.09%)
Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes,...

ONTX : 2.51 (-3.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Support & Resistance

2nd Resistance Point 2.77
1st Resistance Point 2.68
Last Price 2.51
1st Support Level 2.53
2nd Support Level 2.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart